The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > Science & Technology: The Evolution of Oncologic Drug Development

Science & Technology: The Evolution of Oncologic Drug Development

Posted 01 January 2009 | By

Despite a doubling in the number of candidates in the cancer drug pipeline from 1990 through 2006, the overall US approval rate for cancer drugs remains low (8%).1

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe